Compare JPMorgan Chase & Co (JPM) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Oscar Health Inc — how do they compare? JPMorgan Chase & Co trades at $333.32 (market cap $880.98B), while Oscar Health Inc trades at $33.4 (market cap $10.22B). The key difference: JPMorgan Chase & Co is far larger — about 86.2× Oscar Health Inc's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Oscar Health Inc for 15 Days on average.
| JPM | OSCR | |
|---|---|---|
Market Cap | $880.98B | $10.22B |
Volume | 7,721,661 | 4,123,394 |
Sector | Financials | Health |
52-Week High | $365.18 | $33.81 |
52-Week Low | $282.84 | $10.85 |
Typical Hold Time | 127 Days | 15 Days |
Enterprise Value | $1.82T | $6.57B |
Dividend Yield | 1.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $332.99, up 1.03% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to a projected $194.9B in 2026. The stock shows a P/E of 14.2 and ROE of 18.43%, supported by a 'Moderate Buy' analyst consensus and a $373.18 price target. News highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
Outlook: JPM offers value with solid profitability and analyst upside, but risks include geopolitical tensions and cybersecurity threats. The stock's bearish technicals near support at $327 suggest caution, though institutional buying and high ROE provide stability. Investors should weigh strong fundamentals against macroeconomic headwinds highlighted in recent news.
OSCR trades at $33.41, up 1.52% today, with a bullish technical signal and strong recent earnings beats in Q1 and Q2 2026. The stock shows robust revenue growth, with 2026 revenue projected at $15.3B and a return to profitability. Analyst sentiment is mixed but leans positive, with a consensus price target of $34.00. Recent news highlights market share gains and raised 2026 guidance, though the stock faces tests from rising medical costs.
The outlook is cautiously optimistic, driven by scalable growth in the ACA market and margin expansion opportunities. Key risks include medical cost pressures and competitive threats. Upside potential exists if the company executes on its 2029 EPS target of $4+, but investors should monitor profitability sustainability amid cost headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
